Report: Blood Disorder Treatments TOC

Blood Disorder Treatments
Chapter 1 - EXECUTIVE SUMMARY
- EXECUTIVE SUMMARY
- Summary Table: MARKET SIZE OF WORLDWIDE BLOOD DISORDER TREATMENTS BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2012 ($ MILLIONS)
- Summary Figure: MARKET SIZE OF BLOOD DISORDER TREATMENTS BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2005-2012 ($ MILLIONS)
Chapter 2 - INDUSTRY OVERVIEW
- STRUCTURE AND FUNCTION OF THE HEMATOLOGICAL SYSTEM
- BONE MARROW
- BLOOD CELLS
  - Red Blood Cells
  - White Blood Cells
  - Platelets
- SPLEEN
- LYMPH SYSTEM
- LIVER
- NORMAL CLOTTING MECHANISMS
- EFFECTS OF AGING ON THE HEMATOLOGIC SYSTEM
- BLOOD-RELATED MEDICAL CONDITIONS
  - ANEMIA
- Table 1 COMMON CAUSES OF ANEMIA
  - Anemia (Continued)
  - Anemia Caused by Decreased Erythrocyte Production
  - Iron Deficiency Anemia
  - Thalassemia
  - Megaloblastic Anemia
  - Vitamin B12 Deficiency
  - Anemia of Chronic Disease
  - Aplastic Anemia
  - Anemia Caused by Blood Loss
  - Anemia Caused by Increased Erythrocyte Destruction
  - Sickle Cell Disease
  - Glucose-6-Phosphate Dehydrogenase Deficiency
  - Acquired Hemolytic Anemia
  - Polycythemia
- Table 2 TYPES OF ANEMIA
- Table 2 (CONTINUED)
  - HEMOPHILIA
- Table 3 COMMON CAUSES OF HEMOPHILIA
  - NEUTROPENIA
- Table 4 COMMON INFECTIOUS CAUSES OF NEUTROPENIA
- Table 5 COMMON MEDICATION CAUSES OF ANEMIA
  - THROMBOCYTOPENIA
- Table 6 COMMON CAUSES OF THROMBOCYTOPENIA
  - THROMBOSIS
    - Thromboembolus
    - Deep Vein Thrombosis
- Table 7 COMMON CAUSES OF THROMBOSIS
  - DEMOGRAPHICS AND STATISTICS
- Table 8 U.S. CASES OF SELECTED CHRONIC CONDITIONS/ DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007
- Table 8 (CONTINUED)
- Figure 1 U.S. CASES OF SELECTED LEADING CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007 (%)
- Table 9 WORLDWIDE CASES OF SELECTED CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007
- Figure 2 WORLDWIDE CASES OF SELECTED LEADING CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007 (%)
- Table 10 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS)
- Figure 3 U.S. POPULATION BY SELECTED AGE GROUPS, 2005-2012 (MILLIONS)
- Table 11 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS)
- Figure 4 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2005-2012 (MILLIONS)
  - LICENSING DISPUTES
    - Licensing Disputes (Continued)
    - Licensing Disputes (Continued)
    - Licensing Disputes (Continued)
  - REBATE ISSUES
  - FDA RESTRICTIONS ON ANEMIA DRUGS
  - TELEMEDICINE FOR HEMOPHILIA
  - HEMOPHILIA AND JOINT DAMAGE
  - EDUCATION
  - COST
  - PHARMACEUTICAL LANDSCAPE CHANGES
    - THE IMPACT OF BIOTECHNOLOGY
      - The Impact of Biotechnology (Continued)
      - The Impact of Biotechnology (Continued)
- Table 12 MARKETED BIOTECHNOLOGY BLOOD TREATMENTS
- Table 12 (CONTINUED)
- Table 13 MARKETED BIOTECHNOLOGY PRODUCT IMPACT
- Table 13 (CONTINUED)
  - BIOGENERIC IMPACT
  - SEDENTARY LIFESTYLES AND DVT
  - MEDICARE AND THE ELDERLY
    - Medicare and the Elderly (Continued)
  - AIRLINE TRAVEL ISSUES
    - Airline Travel Issues (Continued)
  - PHARMACEUTICAL REBATE ISSUES
- PRODUCT SEGMENTS BY TYPE
  - ANEMIA TREATMENTS
    - Aranesp/Nespo (Darbepoetin Alfa)
    - Procrit/Eprex (Epoetin Alfa)
    - Epogen (Epoetin Alfa)
    - NeoRecormon/Epogin (Epoetin Beta)
- Table 14 KEY ANEMIA TREATMENTS
  - Anabolic Steroids
  - Cyanocobalamin and Combinations
  - Erythropoiesis Stimulants
  - Folic Acid and Derivatives
  - Iron and Derivatives
- HEMOPHILIA TREATMENTS
  - Recombinants Group (Baxter)
  - Kogenate
  - NovoSeven
- Table 15 KEY HEMOPHILIA TREATMENTS
  - Antihemophilic Factor
  - Anti-Inhibitor Coagulant Complex
  - Factor IX Complex
- NEUTROPENIA TREATMENTS
  - Neulasta/ Neupopeg (Pegfilgrastim)
  - Neupogen/ Granulokine (Filgrastim)
- Table 16 KEY NEUTROPENIA TREATMENTS
  - Granulocyte Colony Stimulating Factor
  - Granulocyte Macrophage Colony Stimulating Factor
- THROMBOSIS TREATMENTS
  - Lovenox (Enoxaparin Sodium)
  - Plavix (Clopidogrel Bisulfate)
- Table 17 KEY THROMBOSIS TREATMENTS
  - Anticoagulants
  - Antiplatelet Agents
  - Antithrombin III Agents
  - Thrombin Inhibitors
  - Thrombolytic Agents
- NEW APPROVALS
- Table 18 NEWLY APPROVED BLOOD DISORDER TREATMENTS
- Table 18 (CONTINUED)
- Figure 5 PERCENT OF RECENT BLOOD DISORDER APPROVALS BY TREATMENT TYPE (%)
Chapter 3 - MARKET SIZE AND GROWTH
- Table 19 GLOBAL MARKET FOR BLOOD DISORDER TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 6 GLOBAL MARKET FOR BLOOD DISORDER TREATMENTS, 2005-2012 ($ MILLIONS)
  - BLOOD DISORDER TREATMENT MARKET BY GEOGRAPHY
- Table 20 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE BLOOD DISORDER TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 7 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE BLOOD DISORDER TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
  - BLOOD DISORDER TREATMENT MARKETS BY SEGMENT
    - ANEMIA TREATMENTS MARKET
- Table 21 GLOBAL MARKET FOR ANEMIA TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 8 GLOBAL MARKET FOR ANEMIA TREATMENTS, 2005-2012 ($ MILLIONS)
- Table 22 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE ANEMIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 9 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE ANEMIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
  - HEMOPHILIA TREATMENTS MARKET
- Table 23 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 10 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS, 2005-2012 ($ MILLIONS)
- Table 24 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 11 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
  - NEUTROPENIA TREATMENTS MARKET
- Table 25 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 12 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS, 2005-2012 ($ MILLIONS)
- Table 26 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 13 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
  - THROMBOSIS TREATMENTS
- Table 27 GLOBAL MARKET FOR THROMBOSIS TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 14 GLOBAL MARKET FOR THROMBOSIS TREATMENTS, 2005-2012 ($ MILLIONS)
- Table 28 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 15 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
Chapter 4 - RESEARCH AND DEVELOPMENT
- Table 29 SELECTED BLOOD DISORDER TREATMENTS IN DEVELOPMENT
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
  - TREATMENTS AWAITING APPROVAL/PHASE TRIALS
    - AWAITING APPROVAL
      - Angiomax/Angiox
      - Hemopure
      - Mircera/C.E.R.A./R744
      - EPOCH
      - Ferinject
      - Lovenox
      - Plavix
      - Soluble Ferric Pyrophosphate (SFP)
    - PHASE III CLINICAL TRIALS
      - AMG-531
      - Apixaban
      - ATryn
      - AZD-6140
      - Beriplex P/N
      - Idraparinux Long-Acting Pentasaccharide
      - Cangrelor
      - Elaprin
      - Ferumoxytol
      - Hematide
      - Hemospan
      - Hemoxin/Nicosan/Niprisan
      - ICA-17043
      - Mozobil (AMD3100)
      - NovoSeven
      - Oxygent
      - PolyHeme
      - Procrit (Epoetin Alfa)
      - Promacta (Eltrombopag Olamine)
      - Refacto AF
      - Rendix (Dabigatran Etexilate)
      - Rivaroxaban (BAY 59-7939)
Chapter 5 - INDUSTRY STRUCTURE
- COMPETITIVE ANALYSIS
- Table 30 TOTAL MANUFACTURERS' MARKET SHARES OF BLOOD DISORDER TREATMENTS, 2007
- Table 30 (CONTINUED)
- Figure 17 TOTAL MANUFACTURERS' MARKET SHARES OF BLOOD DISORDER TREATMENTS, 2007
  - ANEMIA TREATMENTS
- Table 31 TOTAL MANUFACTURERS' MARKET SHARES OF ANEMIA TREATMENTS, 2007
- Figure 18 TOTAL MANUFACTURERS' MARKET SHARES OF ANEMIA TREATMENTS, 2007 (%)
  - HEMOPHILIA TREATMENTS
- Table 32 TOTAL MANUFACTURERS' MARKET SHARES OF HEMOPHILIA TREATMENTS, 2007
- Figure 19 TOTAL MANUFACTURERS' MARKET SHARES OF HEMOPHILIA TREATMENTS, 2007 (%)
  - NEUTROPENIA TREATMENTS
- Table 33 TOTAL MANUFACTURERS' MARKET SHARES OF NEUTROPENIA TREATMENTS, 2007
- Figure 20 TOTAL MANUFACTURERS' MARKET SHARES OF NEUTROPENIA TREATMENTS, 2007 (%)
  - THROMBOSIS TREATMENTS
- Table 34 TOTAL MANUFACTURERS' MARKET SHARES OF THROMBOSIS TREATMENTS, 2007
- Figure 21 TOTAL MANUFACTURERS' MARKET SHARES OF THROMBOSIS TREATMENTS, 2007
  - INDUSTRY PARTICIPANTS BY PRODUCT TYPE
- Table 35 BLOOD DISORDER TREATMENT MANUFACTURERS BY PRODUCT TYPE, 2007
- Figure 22 BLOOD DISORDER TREATMENT MARKETS-NUMBER OF KEY MANUFACTURERS BY PRODUCT TYPE, 2007 (%)
Chapter 6 - PATENTS
- PATENT ANALYSIS BY MANUFACTURER
- Table 36 SELECTED MANUFACTURER PATENTS FOR BLOOD DISORDER AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
  - PATENTS BY APPLICATION
    - Anemia Applications
    - Hemophilia
    - Neutropenia
    - Thrombosis
  - LEADING MARKET MANUFACTURERS
- Table 37 PATENT ANALYSIS BY SELECTED LEADING BLOOD DISORDER TREATMENT MANUFACTURERS, 1976-PRESENT
Chapter 7 - COMPANY PROFILES
- AMGEN, INC.
- BAXTER INTL., INC.
- BAYER AG
- BIOPURE CORPORATION
- BRISTOL-MYERS SQUIBB CO.
- CHUGAI PHARMACEUTICAL CO., LTD.
- CSL BEHRING
- GENZYME
- TEL: 617/252-7500
- GLAXOSMITHKLINE, PLC
- ICAGEN, INC.
- MEDICINES COMPANY (THE)
- NOVO NORDISK A/S
- ORTHO BIOTECH PRODUCTS, LP
- ROCHE
- SANOFI-AVENTIS
- SCHERING-PLOUGH CORP.
- WYETH
Chapter 8 - APPENDICES
- COMPANY CONTACT INFORMATION
- Table 38 LIST OF COMPANIES
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
  - BLOOD DISORDER ASSOCIATIONS AND RESOURCES CONTACT INFORMATION
    - BLOOD DISORDER ASSOCIATIONS (CONTINUED)
    - BLOOD DISORDER ASSOCIATIONS (CONTINUED)

Blood Disorder Treatments

Table of Contents